Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

970
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
970
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

1.7K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.7K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

550
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
550
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

828
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
828

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Peripheral Artery Disease and Type 2 Diabetes.

Journal of the American Heart Association·2026
Same author

AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Diagnostic Approach to Left Ventricular Hypertrophy: A Review.

US cardiology·2026
Same author

REN: Anatomically-Informed Mixture-of-Experts for Interstitial Lung Disease Diagnosis.

IEEE transactions on medical imaging·2026
Same author

Outcomes of TAVR Plus TEVAR Versus TAVR Alone in Patients with Concomitant Aortic Stenosis and Thoracic Aortic Aneurysm.

Heart, lung & circulation·2026
Same author

Transcatheter Tricuspid Valve Intervention Versus Optimal Medical Therapy in Symptomatic Tricuspid Regurgitation: A Systematic Review and Meta-Analysis of Randomized and Observational Studies.

The American journal of cardiology·2026

Related Experiment Video

Updated: Feb 22, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K

Cardiogenic Shock: Current Evidence, Guideline Perspectives, and Outcomes.

Shashank Shekhar1, Ankit Agrawal2, Hussein Almadhoun3

  • 1University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH.

Journal of Cardiothoracic and Vascular Anesthesia
|February 20, 2026
PubMed
Summary
This summary is machine-generated.

Cardiogenic shock (CS) is a major cause of hospital death, affecting 40,000-50,000 annually. Despite advances, 30-day mortality remains high, highlighting critical gaps in care.

Keywords:
Cardiogenic shockmechanical circulatory support

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.1K

Related Experiment Videos

Last Updated: Feb 22, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.1K

Area of Science:

  • Cardiology
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) is a severe complication of acute myocardial infarction and other cardiac conditions.
  • It is associated with high in-hospital mortality rates, ranging from 30% to 60% within 30 days.
  • Despite advancements in treatment, outcomes for CS patients remain suboptimal.

Purpose of the Study:

  • To review current definitions and staging systems for cardiogenic shock.
  • To summarize landmark clinical trials and evolving guideline recommendations for CS management.
  • To highlight trends in outcomes and identify persistent gaps in patient care.

Main Methods:

  • This is a review article synthesizing existing literature.
  • It involves summarizing data from clinical trials and guideline documents.
  • The focus is on definitions, staging, therapeutic strategies, and outcomes.

Main Results:

  • Significant heterogeneity exists in clinical trial designs and data reporting for CS.
  • Management strategies for CS patients show considerable variability.
  • Despite therapeutic advances, short-term mortality rates remain alarmingly high.

Conclusions:

  • Cardiogenic shock continues to be a critical clinical challenge with poor prognoses.
  • Standardization of definitions, staging, and management protocols is needed.
  • Further research and optimized care strategies are essential to improve CS outcomes.